The Glypromate failure, page-16

Fast Track Designation is where there are either no or inadequate drugs to patient populations they go on market on phase II data & Phase III trials are run concurrently over the next few years. I don't know why you would want to wait another few years with significant capital burn if you had the option to be on market both for the company to earn to revenue but more importantly so the drug is available to patients. It's one of if the not the most sort after FDA rulings & something like basically all of the targets NEU are chasing fit perfectly with the type of disease & populations Fast Track is designed for.